TABLE 3.
Means (standard errors) of utilities, QALYs and capabilities
| Mean value per participant (SE) | |||||||
|---|---|---|---|---|---|---|---|
| Category | Featback (n = 88) | Featback + expert patient support (n = 90) | Expert patient support (n = 87) | Waiting list (n = 90) | Total (n = 355) | Pooled F‐statistic | |
| EQ‐5D‐5L utilities | |||||||
| Postintervention (T1; 8 weeks) | 0.68 (0.03) | 0.68 (0.03) | 0.61 (0.03) | 0.58 (0.03) | 0.64 (0.01) | F(3, 333) = 3.01, p = .03 | |
| 3‐month follow‐up (T2) | 0.62 (0.03) | 0.68 (0.03) | 0.60 (0.03) | 0.58 (0.04) | 0.62 (0.02) | F(3, 326) = 1.88, p = .13 | |
| 6‐month follow‐up (T3) | 0.69 (0.03) | 0.69 (0.03) | 0.62 (0.03) | 0.60 (0.04) | 0.65 (0.02) | F(3, 321) = 1.90, p = .13 | |
| 9‐month follow‐up (T4) | 0.61 (0.04) | 0.65 (0.04) | 0.63 (0.04) | 0.62 (0.04) | 0.63 (0.02) | F(3, 311) = 0.19, p = .91 | |
| 12‐month follow‐up (T5) | 0.66 (0.03) | 0.71 (0.03) | 0.66 (0.03) | 0.64 (0.04) | 0.67 (0.02) | F(3, 317) = 0.61, p = .61 | |
| EQ‐5D Visual Analogue Scale utilities | |||||||
| Postintervention (T1; 8 weeks) | 0.60 (0.02) | 0.59 (0.02) | 0.55 (0.02) | 0.55 (0.02) | 0.57 (0.01) | F(3, 331) = 1.05, p = .37 | |
| 3‐month follow‐up (T2) | 0.55 (0.02) | 0.56 (0.02) | 0.55 (0.02) | 0.57 (0.02) | 0.56 (0.01) | F(3, 333) = 0.22, p = .88 | |
| 6‐month follow‐up (T3) | 0.61 (0.02) | 0.57 (0.02) | 0.54 (0.02) | 0.58 (0.02) | 0.57 (0.01) | F(3, 325) = 1.77, p = .15 | |
| 9‐month follow‐up (T4) | 0.57 (0.02) | 0.59 (0.02) | 0.56 (0.02) | 0.59 (0.02) | 0.58 (0.01) | F(3, 318) = 0.43, p = .73 | |
| 12‐month follow‐up (T5) | 0.60 (0.02) | 0.61 (0.02) | 0.57 (0.02) | 0.59 (0.02) | 0.59 (0.01) | F(3, 326) = 0.52, p = .67 | |
| ICECAP‐A capability values | |||||||
| Postintervention (T1; 8 weeks) | 0.69 (0.02) | 0.68 (0.02) | 0.63 (0.02) | 0.65 (0.03) | 0.66 (0.01) | F(3, 329) = 1.40, p = .24 | |
| 3‐month follow‐up (T2) | 0.68 (0.02) | 0.69 (0.02) | 0.62 (0.02) | 0.66 (0.03) | 0.66 (0.01) | F(3, 324) = 1.48, p = .22 | |
| 6‐month follow‐up (T3) | 0.70 (0.03) | 0.69 (0.03) | 0.64 (0.03) | 0.65 (0.03) | 0.67 (0.03) | F(3, 316) = 1.01, p = .39 | |
| 9‐month follow‐up (T4) | 0.67 (0.03) | 0.68 (0.03) | 0.65 (0.03) | 0.69 (0.03) | 0.67 (0.01) | F(3, 305) = 0.44, p = .72 | |
| 12‐month follow‐up (T5) | 0.72 (0.02) | 0.72 (0.03) | 0.64 (0.03) | 0.72 (0.03) | 0.70 (0.01) | F(3, 313) = 2.09, p = .10 | |
| Total QALYs EQ‐5D‐5L a | 0.75 (0.03) | 0.78 (0.03) | 0.71 (0.03) | 0.69 (0.03) |
0.74 (0.02) |
F(3, 337) = 1.87, p = .14 | |
| Total QALYs EQ‐5D Visual Analogue Scale a | 0.67 (0.02) | 0.64 (0.02) | 0.69 (0.02) | 0.65 (0.02) | 0.66 (0.01) | F(3, 339) = 0.74, p = .53 | |
| Total capability values ICECAP‐A a | 0.79 (0.02) | 0.79 (0.02) | 0.73 (0.02) | 0.77 (0.03) | 0.77 (0.01) |
F(3, 328) = 1.31, p = .27 |
|
a
Calculated over the entire 14‐month study duration.
Abbreviation: SE, standard error.